Cargando…
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949
Autor principal: | Rosendaal, Frits R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357515/ https://www.ncbi.nlm.nih.gov/pubmed/32674928 http://dx.doi.org/10.1016/j.ijantimicag.2020.106063 |
Ejemplares similares
-
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
por: Machiels, Julian D, et al.
Publicado: (2020) -
Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020) -
Corrigendum to “comparative exome sequencing reveals novel candidate genes for retinitis pigmentosa” [EBioMedicine 56(2020)102792] DOI: https://doi.org/10.1016/j.ebiom.2020.102792
por: Yi, Zhen, et al.
Publicado: (2022) -
Correction to Lancet Microbe 2020; published online May 8. https://doi.org/10.1016/S2666-5247(20)30027-6
Publicado: (2020) -
Correction to Lancet Infect Dis 2020; published online March 23. https://doi.org/10.1016/S1473-3099(20)30162
Publicado: (2020)